10 results about "Artemether" patented technology

The invention relates to the technical field of medicines, and particularly discloses an application of artemether in preparation of an esophageal cancer radiotherapy sensitization medicine. The invention provides the application of artemether in preparation of esophageal cancer radiotherapy sensitization drugs for the first time, and researches find that the artemether can reduce glycolytic activity of esophageal cancer cells by down-regulating expression of key proteins and genes HK2, PKM2 and LDHA in a glycolytic pathway so as to enhance esophageal squamous cell carcinoma radiotherapy sensitization. The invasion ability is inhibited, and cell apoptosis is induced, so that the radiotherapy sensitivity of esophageal cancer cells is enhanced. The artemether and radiotherapy combined treatment provided by the invention is expected to provide a promising treatment scheme for ESCC patients, and has great significance in breaking through the bottleneck of esophageal cancer radiotherapy.

The invention discloses an application of artemether, artesunate or dihydroartemisinin in preparation of a medicine for preventing or treating aflatoxin B1 poisoning. Belongs to the technical field of medicine. The technical problem of detoxification of aflatoxin B1 is solved. The invention provides an application of artemether, artesunate or dihydroartemisinin in preparation of a medicine for treating aflatoxin B1 poisoning diseases. The body can be promoted to detoxify the AFB1.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The application discloses a traditional Chinese medicine composition for treating vaginitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises 12 Chinese herbal medicines, i.e. Sophora flavescens, Phellodendron chinense, Dictamnus dasycarpus, Herba Artemisiae Scopariae, Herba Taraxaci, Chrysanthemum indicum, Herba Portulacae, Cnidium monnieri, Angelica polymorpha, Herba Verbena, Herba Menthae and Saposhnikovia divaricata, and further comprises Salix viminalis, Eucalyptus, Ephedra sinica, anthocyanin quaternary ammonium salt, Ocimum basilicum, Houttuynia cordata, polysialic acid, polydopamine, antibacterial polypeptide modified chitosan hydrochloride and artemether. The traditional Chinese medicine composition is prepared by mixing traditional Chinese medicines and bactericidal and bacteriostatic biocompatible materials to prepare various medicaments. The traditional Chinese medicine composition is used for treating pruritus and leukorrhagia caused by endogenous insect poison and burning of yin fluid, and is used for treating bacterial vaginitis, mycotic vaginitis, trichomonal vaginitis and vulvitis. In clinical tests, the traditional Chinese medicine composition has remarkable treatment effect, and the cure rate is more than 95%.

The invention discloses a compound artemether dispersible tablet and a preparation method thereof. The compound artemether dispersible tablet is prepared from the following components in parts by mass: 20 parts of artemether, 120 parts of benflumetol, 120 to 160 parts of filler, 20 to 30 parts of disintegrating agent, 5 to 15 parts of adhesive, 15 parts of lubricant and 0.5 to 2 parts of surfactant, the disintegrating agent is at least one of croscarmellose sodium, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose. According to the invention, by adopting a double disintegrating agent system (cross-linked sodium carboxymethyl cellulose and carboxymethyl starch sodium) and a surfactant (lauryl sodium sulfate), the disintegration performance and stability of the product are obviously improved, and the adopted wet mixing granulation process is simple and easy to realize industrial production; in the obtained dispersible tablet, the dissolution rate of artemether within 3 hours reaches 85% or above. The product has the advantages of rapid disintegration, good stability and the like, and is suitable for children, old people and patients with dysphagia.

The application discloses an antitumor composition of arsenic trioxide and artesunate for enhancing the drug efficacy of arsenic trioxide, and discloses GA modified pH responsive arsenic trioxide-artesunate double-drug nanoliposome including the composition, the double-drug nanoliposome including glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine polymer, cholesterol, artesunate and calcium arsenate nanoparticles; the glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine and cholesterol form nanoliposome, and the nanoliposome is loaded with artesunate and calcium arsenate nanoparticles; the calcium arsenate nanoparticles contain arsenic trioxide, and a preparation method and application in preparing antitumor drugs are disclosed. The application first co-loads the highly toxic traditional Chinese medicine arsenic trioxide and artesunate to play a synergistic effect, realizes the attenuation and efficiency enhancement of arsenic trioxide through targeted modification delivery and tumor microenvironment response release, and has a good clinical application prospect.

The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.

The present application belongs to the technical field of biological medicine, and particularly relates to a composition for treating atopic dermatitis and application thereof. The mass ratio of each component of the composition is: notoginseng extract: artemether: wujin glycoside: oleanolic acid = (2-4):(2-4):(1-2):(1-2). The composition has the effects of anti-inflammation and anti-itching, and can treat atopic dermatitis, eczema and other diseases. The active ingredients of the composition are all of plant origin, have good safety and the treatment effect on atopic dermatitis, and have a low dosage. The components can achieve a synergistic effect, and show excellent effects. The composition can be applied to functional skin care products (cream, emulsion, essence) and external drugs (ointment).

The application discloses an artemether chiral amino alcohol amide derivative, a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. A series of amide compounds containing an artemisinin unit are constructed by reacting artemether with different chiral amino alcohols. The reaction is an atom-economic reaction. The preparation method has the advantages of simple operation, mild reaction, fast reaction rate, high yield and the like.

The invention discloses an asymmetric hydrogel dressing with double properties and a preparation method and application thereof, and belongs to the field of biomedical materials, the asymmetric hydrogel dressing has a double-layer asymmetric structure comprising a spear layer and a shield layer; wherein the spear layer is a low-crosslinking-density layer and encapsulates liposome of targeted macrophages, the liposome contains a dimer artesunate conjugate and phosphatidylserine, and the spear layer has tissue adhesion; the shield layer is a high-crosslinking-density layer and is used for providing mechanical support and foreign matter adhesion resistance; the hydrogel dressing can synergistically release artesunate and copper ions, and strongly activates autophagy of macrophages by synergistically acting on PI3K / AKT / mTOR and AMPK / mTOR signal pathways, so that chronic inflammation is relieved, collagen deposition is promoted, and wound healing is accelerated. The invention provides an innovative intelligent dressing for treating complicated chronic wounds such as diabetic foot ulcer.